Bisphosphonates are the most clinically important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption.
Currently, seven bisphosphonates have the approval of the United States Food and Drug Administration.
The most common adult diseases treated with bisphosphonates include osteoporosis, Paget disease, and metastatic bone disease.
The treatment of pediatric disorders such as osteogenesis imperfecta and fibrous dysplasia with bisphosphonates has gained momentum, and initial investigations have demonstrated an acceptable safety profile.
Currently, there is a lack of long-term follow-up data, which will be necessary for the development of responsible guidelines for therapy.